Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease

March 4, 2022 updated by: Alexander Achalandabaso, University of Jaén
Interventional study to show the effects of strength exercise on fall risk in elderly with Alzheimer's disease

Study Overview

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Andalucía
      • Jaén, Andalucía, Spain
        • A.F.A La Estrella
    • Madrid
      • Alcalá De Henares, Madrid, Spain, 28805
        • Alexander achalandabaso

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • accept to participate in the study, through informed consent
  • subjects aged 60 or over with medical diagnosis of Azlheimer´s disease
  • minimal physical and mental state to perform the cognitive tests and strength exercise routine

Exclusion Criteria:

  • Neurodegenerative disease other than Alzheimer's disease
  • Suffering from serious somatic or psychiatric illnesses
  • Patients who have practiced strength exercise regularly

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
This is the group that receives strength exercise in addition to usual treatment
Strength exercise protocol for upper and lower limbs, using weights and elastic bands
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
Other: Control group
This is the group that only receives usual treatment
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline Short physical performance battery (SPPB) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
Informs about fall risk and mobility Score: 0-12 High score means better result
Baseline, 3 and 6 months (3 months after intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline Activities specific balance confidence scale (ABC scale) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
This questionnaire allows to measure the balance of a person Score: 0-100% High percentage means better result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline Lawton Instrumental Activities of Daily Living Scale (IADL) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
This tool gives us information about performance in activities of daily living Score: 0-8 High score means better result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline Quality of life Alzheimer Disease (QoL-AD) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
Through this test we can know the level of quality of life of users who suffer from this disease Score: 0-52 High score means better result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline FRAIL test at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
This rapid test allows to determine the state of frailty of older people Score: 0-5 High score means worst result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline Mini Mental State Examination (MMSE) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
This test gives us information about the cognitive performance of the participants Score: 0-30 High score means better result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline Neuropsychiatric Inventory (NPI-Q) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
This tool allows to specify the neuropsychiatric symptoms patients present Score: 0-36 High score means worst result
Baseline, 3 and 6 months (3 months after intervention)
Change from baseline Manual dynamometry at 1,2,3 and 6 months
Time Frame: Baseline, 1, 2, 3 and 6 months (3 months after intervention)
This test allows to quantify force an individual presents in a simple way Score: 0-∞ High score means better result
Baseline, 1, 2, 3 and 6 months (3 months after intervention)
Modified Borg scale
Time Frame: 3 times/week during strength exercises sessions
In this way we can measure the level of perceived exertion during the intervention with strength exercise Score: 0-10 High score means more fatigue
3 times/week during strength exercises sessions
Change from baseline One Maximum repetition strength test (1 MR) at 1,2,3 and 6 months
Time Frame: Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)
Allows you easily to assess maximum strength Score: 0-∞ High score means more strength level
Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2021

Primary Completion (Actual)

December 10, 2021

Study Completion (Actual)

March 4, 2022

Study Registration Dates

First Submitted

July 19, 2021

First Submitted That Met QC Criteria

July 28, 2021

First Posted (Actual)

July 29, 2021

Study Record Updates

Last Update Posted (Actual)

March 7, 2022

Last Update Submitted That Met QC Criteria

March 4, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Strength exercise

Subscribe